{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:08:21Z","timestamp":1771646901726,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"23","license":[{"start":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T00:00:00Z","timestamp":1408320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T00:00:00Z","timestamp":1408320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2015,6,4]]},"DOI":"10.1038\/onc.2014.237","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T10:28:36Z","timestamp":1408357716000},"page":"3036-3052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin"],"prefix":"10.1038","volume":"34","author":[{"given":"B T","family":"Paul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ridgway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W M","family":"ElShamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,18]]},"reference":[{"key":"BFonc2014237_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2013.03.021","volume":"130","author":"N Auersperg","year":"2013","unstructured":"Auersperg N . Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis? Gynecol Oncol 2013; 130: 246\u2013251.","journal-title":"Gynecol Oncol"},{"key":"BFonc2014237_CR2","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1517\/13543784.2010.515585","volume":"19","author":"K Matsuo","year":"2010","unstructured":"Matsuo K, Lin YG, Roman LD, Sood AK . Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs 2010; 19: 1339\u20131354.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFonc2014237_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1634\/theoncologist.2009-0013","volume":"14","author":"S Banerjee","year":"2009","unstructured":"Banerjee S, Gore M . The future of targeted therapies in ovarian cancer. Oncologist 2009; 14: 706\u2013716.","journal-title":"Oncologist"},{"key":"BFonc2014237_CR4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/emmm.201100176","volume":"3","author":"D Torti","year":"2011","unstructured":"Torti D, Trusolino L . Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011; 3: 623\u2013636.","journal-title":"EMBO Mol Med"},{"key":"BFonc2014237_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/jso.21749","volume":"103","author":"F McCormick","year":"2011","unstructured":"McCormick F . Cancer therapy based on oncogene addiction. J Surg Oncol 2011; 103: 464\u2013467.","journal-title":"J Surg Oncol"},{"key":"BFonc2014237_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1600-0463.2008.01037.x","volume":"116","author":"DW Felsher","year":"2008","unstructured":"Felsher DW . Tumor dormancy and oncogene addiction. APMIS 2008; 116: 629\u2013637.","journal-title":"APMIS"},{"key":"BFonc2014237_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ccr.2009.12.047","volume":"17","author":"Q Sheng","year":"2010","unstructured":"Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J et al. An activated ErbB3\/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010; 17: 298\u2013310.","journal-title":"Cancer Cell"},{"key":"BFonc2014237_CR8","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/ncb1171","volume":"6","author":"WM ElShamy","year":"2004","unstructured":"ElShamy WM, Livingston DM . Identification of BRCA1-IRIS, a BRCA1 locus product. Nat Cell Biol 2004; 6: 954\u2013967.","journal-title":"Nat Cell Biol"},{"key":"BFonc2014237_CR9","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1016\/j.yexcr.2006.06.021","volume":"312","author":"E Nakuci","year":"2006","unstructured":"Nakuci E, Mahner S, Direnzo J, ElShamy WM . BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. Exp Cell Res 2006; 312: 3120\u20133131.","journal-title":"Exp Cell Res"},{"key":"BFonc2014237_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/ijc.22597","volume":"121","author":"L Hao","year":"2007","unstructured":"Hao L, ElShamy WM . BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3\/VHR. Int J Cancer 2007; 121: 39\u201346.","journal-title":"Int J Cancer"},{"key":"BFonc2014237_CR11","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1038\/onc.2010.262","volume":"29","author":"K Chock","year":"2010","unstructured":"Chock K, Allison JM, ElShamy WM . BRCA1-IRIS overexpression abrogates UV-induced p38MAPK\/p53 and promotes proliferation of damaged cells. Oncogene 2010; 29: 5274\u20135285.","journal-title":"Oncogene"},{"key":"BFonc2014237_CR12","doi-asserted-by":"publisher","first-page":"e34102","DOI":"10.1371\/journal.pone.0034102","volume":"7","author":"Y Shimizu","year":"2012","unstructured":"Shimizu Y, Luk H, Horio D, Miron P, Griswold M, Iglehart D et al. BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. PLoS ONE 2012b; 7: e34102.","journal-title":"PLoS ONE"},{"key":"BFonc2014237_CR13","doi-asserted-by":"publisher","first-page":"8782","DOI":"10.1158\/0008-5472.CAN-10-1352","volume":"70","author":"KL Chock","year":"2010","unstructured":"Chock KL, Allison JM, Shimizu Y, ElShamy WM . BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Cancer Res 2010; 70: 8782\u20138791.","journal-title":"Cancer Res"},{"key":"BFonc2014237_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/IGC.0b013e31827ad2b8","volume":"23","author":"L Chen","year":"2013","unstructured":"Chen L, Liang L, Yan X, Liu N, Gong L, Pan S et al. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer. Int J Gynecol Cancer 2013; 23: 256\u2013263.","journal-title":"Int J Gynecol Cancer"},{"key":"BFonc2014237_CR15","first-page":"2973","volume":"58","author":"AX Liu","year":"1998","unstructured":"Liu AX, Testa JR, Hamilton TC, Jove R, Nicosia SV, Cheng JQ . AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res 1998; 58: 2973\u20132977.","journal-title":"Cancer Res"},{"key":"BFonc2014237_CR16","first-page":"407","volume":"20","author":"C Page","year":"2000","unstructured":"Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M et al. Overexpression of Akt\/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000; 20: 407\u2013416.","journal-title":"Anticancer Res"},{"key":"BFonc2014237_CR17","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2174\/138945011796150307","volume":"12","author":"M Monsalve","year":"2011","unstructured":"Monsalve M, Olmos Y . The complex biology of FOXO. Curr Drug Targets 2011; 12: 1322\u20131350.","journal-title":"Curr Drug Targets"},{"key":"BFonc2014237_CR18","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1158\/0008-5472.CAN-12-3767","volume":"73","author":"EE Santo","year":"2013","unstructured":"Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM . FOXO3a is a major target of inactivation by PI3K\/AKT signaling in aggressive neuroblastoma. Cancer Res 2013; 73: 2189\u20132198.","journal-title":"Cancer Res"},{"issue":"Suppl 4","key":"BFonc2014237_CR19","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0959-8049(01)00230-1","volume":"37","author":"Y Yarden","year":"2001","unstructured":"Yarden Y . The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 (Suppl 4): S3\u2013S8.","journal-title":"Eur J Cancer"},{"key":"BFonc2014237_CR20","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.2005.04.8397","volume":"24","author":"B Tanner","year":"2006","unstructured":"Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006; 24: 4317\u20134323.","journal-title":"J Clin Oncol"},{"key":"BFonc2014237_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039\u20131043.","journal-title":"Science"},{"key":"BFonc2014237_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature05474","volume":"445","author":"NV Sergina","year":"2007","unstructured":"Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437\u2013441.","journal-title":"Nature"},{"key":"BFonc2014237_CR23","first-page":"232","volume":"1785","author":"JM Lafky","year":"2008","unstructured":"Lafky JM, Wilken JA, Baron AT, Maihle NJ . Clinical implications of the ErbB\/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008; 1785: 232\u2013265.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2014237_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ygyno.2010.08.008","volume":"119","author":"SV Blank","year":"2010","unstructured":"Blank SV, Christos P, Curtin JP, Goldman N, Runowitcz CD, Sparano JA et al. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol 2010; 119: 451\u2013456.","journal-title":"Gynecol Oncol"},{"key":"BFonc2014237_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2010","unstructured":"Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo Ol Serra V, Majumder PK et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2010; 19: 58\u201371.","journal-title":"Cancer Cell"},{"key":"BFonc2014237_CR26","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2009.22.3354","volume":"28","author":"S Makhija","year":"2010","unstructured":"Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010; 28: 1215\u20131223.","journal-title":"J Clin Oncol"},{"key":"BFonc2014237_CR27","doi-asserted-by":"publisher","first-page":"568938","DOI":"10.1155\/2010\/568938","volume":"2010","author":"DR Siwak","year":"2010","unstructured":"Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010; 2010: 568938.","journal-title":"J Oncol"},{"key":"BFonc2014237_CR28","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/jnr.490350503","volume":"35","author":"Y Masana","year":"1993","unstructured":"Masana Y, Wanaka A, Kato H, Asai T, Tohyama M . Localization of trkB mRNA in postnatal brain development. J Neurosci Res 1993; 35: 468\u2013479.","journal-title":"J Neurosci Res"},{"key":"BFonc2014237_CR29","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/0955-0674(95)80073-5","volume":"7","author":"MC Birling","year":"1995","unstructured":"Birling MC, Price J . Influence of growth factors on neuronal differentiation. Curr Opin Cell Biol 1995; 7: 878\u2013884.","journal-title":"Curr Opin Cell Biol"},{"key":"BFonc2014237_CR30","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1523\/JNEUROSCI.17-10-03623.1997","volume":"17","author":"S Alc\u00e1ntara","year":"1997","unstructured":"Alc\u00e1ntara S, Fris\u00e9n J, del R\u00edo JA, Soriano E, Barbacid M, Silos-Santiago I . TrkB signaling is required for postnatal survival of CNS neurons and protects hippocampal and motor neurons from axotomy-induced cell death. J Neurosci 1997; 17: 3623\u20133633.","journal-title":"J Neurosci"},{"key":"BFonc2014237_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1349-7006.2007.00722.x","volume":"99","author":"X Yu","year":"2008","unstructured":"Yu X, Liu L, Cai B, He Y, Wan X . Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci 2008; 99: 543\u2013552.","journal-title":"Cancer Sci"},{"key":"BFonc2014237_CR32","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/030089161109700613","volume":"97","author":"W Zheng","year":"2011","unstructured":"Zheng W, Dai Q, Tao P, Sun A, Wang Y, Bao L et al. Overexpression of tyrosine kinase receptor B promotes metastasis of ovarian serous adenocarcinoma by lymphangiogenesis. Tumori 2011; 97: 756\u2013761.","journal-title":"Tumori"},{"key":"BFonc2014237_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.lungcan.2012.07.011","volume":"78","author":"K Okamura","year":"2012","unstructured":"Okamura K, Harada T, Wang S, Ijichi K, Furuyama K, Koga T et al. Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. Lung Cancer 2012; 78: 100\u2013106.","journal-title":"Lung Cancer"},{"key":"BFonc2014237_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cytogfr.2012.06.004","volume":"23","author":"H Hondermarck","year":"2012","unstructured":"Hondermarck H . Neurotrophins and their receptors in breast cancer. Cytokine Growth Factor Rev 2012; 23: 357\u2013365.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFonc2014237_CR35","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.bbamcr.2011.01.007","volume":"1813","author":"H Huang","year":"2011","unstructured":"Huang H, Tindall DJ . Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta 2011; 1813: 1961\u20131964.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2014237_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/08977191003677402","volume":"28","author":"A Ricci","year":"2010","unstructured":"Ricci A, Mariotta S, Pompili E, Mancini R, Bronzetti E, De Vitis C et al. Neurotrophin system activation in pleural effusions. Growth Factors 2010; 28: 221\u2013231.","journal-title":"Growth Factors"},{"key":"BFonc2014237_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1600-0463.2009.02577.x","volume":"118","author":"Y Yu","year":"2010","unstructured":"Yu Y, Zhang S, Wang X, Yang Z, Ou G . Overexpression of TrkB promotes the progression of colon cancer. APMIS 2010; 118: 188\u2013195.","journal-title":"APMIS"},{"key":"BFonc2014237_CR38","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/onc.2009.486","volume":"29","author":"ME Kupferman","year":"2010","unstructured":"Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 2010; 29: 2047\u20132059.","journal-title":"Oncogene"},{"key":"BFonc2014237_CR39","doi-asserted-by":"publisher","first-page":"6221","DOI":"10.1158\/0008-5472.CAN-07-0121","volume":"67","author":"TR Geiger","year":"2007","unstructured":"Geiger TR, Peeper DS . Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res 2007; 67: 6221\u20136229.","journal-title":"Cancer Res"},{"key":"BFonc2014237_CR40","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1128\/MCB.01164-08","volume":"29","author":"MA Smit","year":"2009","unstructured":"Smit MA, Geiger TR, Song JY, Gitelman I, Peeper DS . A Twist-Snail axis critical for TrkB-induced epithelial\u2013mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol 2009; 29: 3722\u20133737.","journal-title":"Mol Cell Biol"},{"key":"BFonc2014237_CR41","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1038\/onc.2011.96","volume":"30","author":"MA Smit","year":"2011","unstructured":"Smit MA, Peeper DS . Zeb1 is required for TrkB-induced epithelial\u2013mesenchymal transition, anoikis resistance and metastasis. Oncogene 2011; 30: 3735\u20133744.","journal-title":"Oncogene"},{"key":"BFonc2014237_CR42","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/nature02765","volume":"430","author":"S Douma","year":"2004","unstructured":"Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS . Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004; 430: 1034\u20131039.","journal-title":"Nature"},{"key":"BFonc2014237_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbrc.2009.08.101","volume":"389","author":"RW Matheny Jr","year":"2009","unstructured":"Matheny RW Jr, Adamo ML . Role of Akt isoforms in IGF-I-mediated signaling and survival in myoblasts. Biochem Biophys Res Commun 2009; 389: 117\u2013121.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2014237_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/ncb1676","volume":"10","author":"JY Yang","year":"2008","unstructured":"Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008; 10: 138\u2013148.","journal-title":"Nat Cell Biol"},{"key":"BFonc2014237_CR45","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.1038\/onc.2010.309","volume":"29","author":"MP Ponnusamy","year":"2010","unstructured":"Ponnusamy MP, Lakshmanan I, Jain M, Das S, Chakraborty S, Dey P et al. MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene 2010; 29: 5741\u20135754.","journal-title":"Oncogene"},{"key":"BFonc2014237_CR46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1006\/gyno.1995.0008","volume":"59","author":"KA O\u2019Hanlan","year":"1995","unstructured":"O\u2019Hanlan KA, Kargas S, Schreiber M, Burrs D, Mallipeddi P, Longacre T et al. Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection. Gynecol Oncol 1995; 59: 200\u2013206.","journal-title":"Gynecol Oncol"},{"key":"BFonc2014237_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.canlet.2008.08.027","volume":"273","author":"D Weng","year":"2009","unstructured":"Weng D, Song X, Xing H, Ma X, Xia X, Weng Y et al. Implication of the Akt2\/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett 2009; 273: 257\u2013265.","journal-title":"Cancer Lett"},{"key":"BFonc2014237_CR48","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejogrb.2009.04.035","volume":"146","author":"HY Zhang","year":"2009","unstructured":"Zhang HY, Zhang PN, Sun H . Aberration of the PI3K\/AKT\/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol 2009; 146: 81\u201386.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"BFonc2014237_CR49","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3892\/ol.2013.1258","volume":"5","author":"L Jiang","year":"2013","unstructured":"Jiang L, Cao XC, Cao JG, Liu F, Quan MF, Sheng XF et al. Casticin induces ovarian cancer cell apoptosis by repressing FoxM1 through the activation of FOXO3a. Oncol Lett 2013; 5 1605\u20131610.","journal-title":"Oncol Lett"},{"key":"BFonc2014237_CR50","first-page":"121","volume":"29","author":"Z Liguang","year":"2007","unstructured":"Liguang Z, Peishu L, Hongluan M, Hong J, Rong W, Wachtel MS et al. Survivin expression in ovarian cancer. Exp Oncol 2007; 29: 121\u2013125.","journal-title":"Exp Oncol"},{"key":"BFonc2014237_CR51","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1242\/dev.124.10.1877","volume":"124","author":"S Jungbluth","year":"1997","unstructured":"Jungbluth S, Koentges G, Lumsden A . Coordination of early neural tube development by BDNF\/trkB. Development 1997; 124: 1877\u20131885.","journal-title":"Development"},{"key":"BFonc2014237_CR52","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nn.3333","volume":"16","author":"D Puehringer","year":"2013","unstructured":"Puehringer D, Orel N, L\u00fcningschr\u00f6r P, Subramanian N, Herrmann T, Chao MV et al. EGF transactivation of Trk receptors regulates the migration of newborn cortical neurons. Nat Neurosci 2013; 16: 407\u2013415.","journal-title":"Nat Neurosci"},{"key":"BFonc2014237_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.regpep.2012.10.005","volume":"180","author":"W Yue","year":"2010","unstructured":"Yue W, Song L, Fu G, Li Y, Liu H . Neuregulin-1\u03b2 regulates tyrosine kinase receptor expression in cultured dorsal root ganglion neurons with excitotoxicity induced by glutamate. Regul Pept 2010; 180: 33\u201342.","journal-title":"Regul Pept"},{"key":"BFonc2014237_CR54","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/ijms12021009","volume":"12","author":"M Ween","year":"2011","unstructured":"Ween M, Oehler M, Ricciardelli C . Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 2011; 12: 1009\u20131029.","journal-title":"Int J Mol Sci"},{"key":"BFonc2014237_CR55","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature02369","volume":"428","author":"HG Wendel","year":"2004","unstructured":"Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428 332\u2013337.","journal-title":"Nature"},{"key":"BFonc2014237_CR56","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1200\/JCO.2005.05.4221","volume":"24","author":"MS Gordon","year":"2006","unstructured":"Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006; 24: 4324\u20134332.","journal-title":"J Clin Oncol"},{"key":"BFonc2014237_CR57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1177\/030089160409000102","volume":"90","author":"S Brader","year":"2004","unstructured":"Brader S, Eccles SA . Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 2004; 90: 2\u20138.","journal-title":"Tumori"},{"key":"BFonc2014237_CR58","doi-asserted-by":"publisher","first-page":"33538","DOI":"10.1074\/jbc.M404115200","volume":"279","author":"H Kim","year":"2004","unstructured":"Kim H, Li Q, Hempstead BL, Madri JA . Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells. J Biol Chem 2004; 279: 33538\u201333546.","journal-title":"J Biol Chem"},{"key":"BFonc2014237_CR59","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2004.06.006","volume":"117","author":"J Yang","year":"2004","unstructured":"Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117 927\u2013939.","journal-title":"Cell"},{"key":"BFonc2014237_CR60","doi-asserted-by":"publisher","first-page":"19347","DOI":"10.1074\/jbc.274.27.19347","volume":"274","author":"S Pece","year":"1999","unstructured":"Pece S, Chiariello M, Murga C, Gutkind JS . Activation of the protein kinase Akt\/PKB by the formation of E-cadherin-mediated cell\u2013cell junctions. Evidence for the association of phosphatidylinositol 3-kinase with the E-cadherin adhesion complex. J Biol Chem 1999; 274: 19347\u201319351.","journal-title":"J Biol Chem"},{"key":"BFonc2014237_CR61","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/29.4.6166661","volume":"29","author":"S-M Hsu","year":"1981","unstructured":"Hsu S-M, Raine L, Fanger H . Use of avidin\u2013biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577\u2013580.","journal-title":"J Histochem Cytochem"},{"key":"BFonc2014237_CR62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1369\/jhc.2009.953554","volume":"58","author":"KR Choudhury","year":"2010","unstructured":"Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG . A robust automated measure of average antibody staining in immunohistochemistry images. J Histochem Cytochem 2010; 58: 95\u2013107.","journal-title":"J Histochem Cytochem"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2014237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2014237","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2014237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:11:39Z","timestamp":1647893499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2014237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,18]]},"references-count":62,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2015,6,4]]}},"alternative-id":["BFonc2014237"],"URL":"https:\/\/doi.org\/10.1038\/onc.2014.237","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,18]]},"assertion":[{"value":"14 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}